Enlicitide: The first oral PCSK9 inhibitor approved for treatment of hypercholesterolemia.
The first oral cholesterol-lowering drug of its class cuts LDL-C by 60% in sustained trials, potentially offering patients a simpler alternative to injections.
Enlicitide (FDA-approved July 2026) is the first oral PCSK9 inhibitor: a macrocyclic peptide achieving ~60% LDL-C reduction in phase III CORALreef trials (maintained 52 weeks); CV outcomes data pending from ongoing CORALreef Outcomes trial. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- drug_review_commentary
- Category
- sentinel
- Maturity
- Validated
- Journal
- Drug Discoveries and Therapeutics
Why it surfaced
First-in-class oral PCSK9 inhibitor FDA approval is a sentinel drug class event; novelty score of 3 (transformative drug delivery format); high unmet need for oral LDL-lowering in statin-intolerant patients; CV outcomes data pipeline relevant to T7 watchlist.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.